Truist Securities Reiterates Buy Rating on Progyny, Inc.
Truist Securities maintains its buy rating and sets a $33 price target for Progyny, Inc, a 22.72% upside from the current price.
Key Points
- Truist Securities reiterated its buy rating on Progyny, Inc. (PGNY) with a $33 price target on June 22, 2026.
- Truist Securities's $33 price target implies 22.72% upside from Progyny, Inc.'s ($PGNY) current $26.89 share price.
- Progyny shares traded around $26.08 on Tuesday, with a market cap of approximately $2.06 billion and a P/E ratio of 34.1.
- Insider transactions included CFO Mark Livingston selling 2,517 shares on June 4, 2026, under a planned sale.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities has reiterated its buy rating on Progyny, Inc. (NasdaqGS: PGNY), maintaining a price target of $33. This update came from analyst Jailendra Singh on June 22, 2026. Shares of Progyny traded at around $26.08 on that day.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Progyny, Inc. Stock Up 3.4%
Shares of NasdaqGS:PGNY traded near $26.08 on Tuesday. Progyny, Inc. has a market cap of about $2.06 billion, with a P/E ratio of 34.1 and a forward P/E of 11.9. The stock has seen a 52-week low of $16.10 and a high of $28.75. Its 50-day moving average is $22.15, while the 200-day moving average is $22.08. The company maintains a current ratio of 2.13 and a quick ratio of 2.07, with a debt-to-equity ratio of 6.21.
$PGNY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Progyny reported revenue of approximately $1.29 billion, reflecting a growth rate of 1.4%. The company's earnings per share (EPS) stood at $0.77. Progyny's net margin was 5.2%, with a return on equity (ROE) of 14.9%. The next earnings report is scheduled for August 6, 2026.
Insider Buying and Selling at Progyny, Inc.
Recent insider transactions included Chief Financial Officer Mark Livingston selling 2,517 shares at an average price of $25.50 on June 4, 2026, as part of a planned sale. Additionally, Executive Vice President and General Counsel Allison Swartz sold 599 shares at $25.08 on the same day, also under a planned sale.
Analysts Set New Price Targets
On June 22, 2026, Truist Securities maintained its buy rating on Progyny, Inc. with a price target of $33. Earlier, on June 2, 2026, B of A Securities also maintained a buy rating with a $31 target. Canaccord Genuity upgraded the stock to a buy with a $30 target on May 19, 2026. Overall, the stock has a consensus rating of "strong buy" with an average price target of $29.73 across 11 analyst opinions.
About Progyny, Inc.
Progyny, Inc. is a healthcare company based in New York, NY, that provides fertility and family-building benefits solutions. The company offers a comprehensive benefits package including fertility treatments, pharmacy benefits, and various support services. Progyny is led by CEO Peter Anevski and employs around 835 people. It was incorporated in 2008 and operates primarily in the United States.
Bottom Line
Truist Securities' reaffirmation of its buy rating on Progyny, Inc. highlights the firm's positive outlook on the company. Investors often track these ratings to gauge market sentiment, though it's important to remember that these analyst updates are forward-looking opinions and not guarantees. Progyny's financial health and strategic positioning in the healthcare sector make it a company to watch.
Get Progyny, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PGNY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.